Congenital hemangioma is a birthmark made of extra blood vessels that is fully formed at birth. It most often appears as a raised, round or oval patch that can look red, purple, or blue, and it may feel warm. Some congenital hemangiomas shrink on their own in the first months to years, while others stay the same size. Babies and young children are the main group affected, and most live healthy lives. Treatment ranges from watchful waiting to ultrasound or MRI monitoring, medicines like propranolol in select cases, laser, or surgery when there is bleeding, pain, ulceration, or trouble with function.
Overview
Congenital hemangiomaSymptoms
Congenital hemangioma is present at birth as a pink to purplish mark, raised or flat, with visible veins. It may feel warm or tender, and occasionally bleeds or forms a sore. Early signs of congenital hemangioma include rapid size changes.
Outlook and prognosis
Most congenital hemangiomas are fully formed at birth and then either shrink quickly in the first months or remain stable long term. Many children need only monitoring; others benefit from targeted care for pain, ulceration, or cosmetic concerns. Overall outcomes are excellent, and life expectancy is normal.
Causes and risk factors
Congenital hemangioma forms before birth from localized overgrowth of blood vessels, likely due to random gene changes in that tissue; it’s not inherited. Known risk factors are limited, with no proven lifestyle or pregnancy exposures; sometimes seen on prenatal ultrasound.
Genetic influences
Genetics play a limited role in congenital hemangioma. Most cases are sporadic, linked to changes in growth signals in the affected area before birth, not inherited. Rarely, somatic gene variants in blood-vessel pathways are found, without clear family patterns.
Diagnosis
Doctors diagnose congenital hemangioma at birth by its characteristic appearance and growth pattern. Ultrasound with Doppler, and sometimes MRI, define depth and blood flow; biopsy is uncommon. Genetic diagnosis of congenital hemangioma is rarely required, used only to exclude mimics.
Treatment and drugs
Treatment for congenital hemangioma depends on size, location, and symptoms. Many are watched closely; pain, ulceration, or bleeding may be managed with wound care, pain relief, and sometimes embolization or surgery. Selected cases benefit from beta-blockers or laser to reduce bulk or complications.
Symptoms
You may notice a firm, purple-red birthmark on your newborn’s skin, sometimes with a pale ring and fine surface veins. It’s present at birth and already fully formed. Early features of congenital hemangioma include a distinct color, a firm feel, and a clear border. Features vary from person to person and can change over time.
A congenital hemangioma is noticeable at birth and does not need time to appear. The area can look like a round or oval birthmark that is either flat or raised.
The surface often looks purple-red or blue with a faint pale ring around it. It may feel firm to the touch, with fine, spidery surface vessels.
You may see small, widened veins on or around the mark and a lighter ring at the edge. The center can look slightly dented or smoother than nearby skin.
These birthmarks range from a few millimeters (less than 1/4 inch) to several centimeters (over an inch) across. They most often appear on the head, neck, trunk, arms, or legs.
How people usually first notice Congenital hemangioma?
Many families first notice a congenital hemangioma at birth because it’s already visible on the skin as a well-defined bump or patch, often round or oval, that can look reddish-purple, blue, or skin-colored with prominent surface veins. Doctors recognize it quickly on the first newborn exam since, unlike common infantile hemangiomas, it does not appear later or grow after birth; some types even begin to shrink within days to weeks. If the spot is large, tense, or near sensitive areas like the eye, or if the baby shows signs such as pallor or rapid heartbeat that could hint at high blood flow through the lesion, clinicians may order an ultrasound to confirm the diagnosis.
Types of Congenital hemangioma
Congenital hemangioma is present at birth and comes in a few well-recognized variants that differ in how they behave over time. Clinicians often describe them in these categories: rapidly involuting, non-involuting, and partially involuting. These variants can look similar at birth but follow different paths in the first months to years of life, which helps guide follow-up and treatment. Knowing the types of congenital hemangioma can clarify what to expect as your child grows.
RICH variant
This stands for rapidly involuting congenital hemangioma. It usually shrinks quickly on its own in the first 6–14 months, often leaving looser skin or small veins. Early symptoms of congenital hemangioma in this type may include a firm, raised birthmark with visible vessels.
NICH variant
This is a non-involuting congenital hemangioma. It does not shrink over time and tends to grow in step with the child’s body, keeping a similar appearance. Some may feel warm or firm to the touch, but they typically remain stable.
PICH variant
This is a partially involuting congenital hemangioma. It shrinks somewhat after birth but then stops, leaving a smaller, persistent lesion. For many, this can mean cosmetic changes improve but a visible mark or small lump remains.
What genetics can tell you about symptoms
Some congenital hemangiomas link to mutations in GNAQ, GNA11, or GNA14, which can drive a fast-growing lump present at birth with a purplish-blue color, warmth, and visible vessels. Certain variants relate to rapid involution (RICH) shrinking early, while others persist (NICH).
Causes and risk factors
Congenital hemangioma starts before birth when a cluster of blood vessels grows abnormally in one spot.
This seems to come from a gene change in that area of skin or tissue that is not inherited and not passed down.
Family history is rare, and most cases happen as a one-off in a child with no known triggers.
No clear lifestyle or environmental risks in pregnancy have been shown, so risk factors for congenital hemangioma remain limited.
Researchers are still learning how these pieces fit together.
Environmental and biological risk factors
Congenital hemangioma is a blood vessel birthmark that is fully formed at birth. Most cases happen without a clear environmental or biological trigger. This section focuses on risks rather than early symptoms of congenital hemangioma. Researchers are still exploring how outside influences interact with our inner biology.
Congenital hemangioma forms when clusters of tiny blood vessels grow too quickly during fetal development. The exact trigger for this overgrowth is unclear, but it is a biological change that starts before birth.
Research has not identified any consistent environmental exposure—such as medications, infections, pollution, or workplace chemicals—that increases risk. Most pregnancies with these findings have no clear external trigger.
Common pregnancy conditions like high blood pressure or diabetes have not shown a reliable association. When a hemangioma is present at birth, the parent’s health history often does not explain it.
Unlike the more common infantile hemangioma, congenital hemangioma is not clearly tied to prematurity or low birth weight. It frequently appears in full-term newborns of average size.
Genetic risk factors
Because these growths are fully formed at birth, the genetics point to changes that arise early in fetal development. Most congenital hemangioma cases are linked to a patch of cells carrying a spontaneous (not inherited) change in genes that steer blood vessel growth, most often GNAQ or GNA11. This helps explain why early symptoms of congenital hemangioma are present from day one. Science continues to uncover how these elements interact.
GNAQ/GNA11 changes: Many congenital hemangiomas carry a tissue-limited change in the GNAQ or GNA11 gene. This boosts signals that tell blood vessels to grow.
Mosaic pattern: The change occurs after conception, so only a cluster of cells is affected. This mosaic pattern makes the lesion localized and explains why it is not typically inherited.
Not hereditary: The gene change is not present in all cells of the body or in eggs or sperm. Family history usually does not increase the chance of a congenital hemangioma.
Early fetal timing: The mutation arises during early fetal development as blood vessels are forming. This timing is why the mass is already fully formed at birth.
Growth signaling overdrive: The altered gene sends stronger growth signals inside vessel cells. That overactivity promotes extra vessel formation and supports the tumor’s development before birth.
Tumor-only testing: Standard blood or saliva DNA tests are typically normal because the change is confined to the lesion. Genetic analysis, when needed, is done on the tumor tissue to identify the driver gene.
Limited syndromic links: Congenital hemangioma usually occurs on its own and is not part of a broader inherited syndrome. Overlap with other vascular conditions is rare and depends on the exact gene change.
Lifestyle risk factors
Lifestyle habits do not cause Congenital hemangioma, but they can influence bleeding, ulceration, pain, and scarring over time. In other words, there are no lifestyle risk factors for Congenital hemangioma in terms of causing it, yet daily choices can shape symptom flares and complications. The points below focus on how lifestyle affects Congenital hemangioma in practical, condition-specific ways.
Rubbing from clothing, straps, or diapers can trigger ulceration or bleeding at the lesion. Choose soft fabrics and avoid tight bands or repetitive pressure on the area.
Sunburn or heat can inflame the lesion and make discoloration appear darker. Use shade, hats, and broad-spectrum sunscreen to reduce irritation and color change.
Heat can increase blood flow and transient swelling or tenderness of the lesion. Extreme cold may dry and crack fragile skin, predisposing to ulceration.
Rough play or contact sports raise the risk of direct trauma and bleeding. Consider padding, protective dressings, or modifying activities until the lesion has involuted or been treated.
Risk prevention
Congenital hemangioma develops before birth, so you can’t prevent it from forming. Prevention is about lowering risk, not eliminating it completely. Knowing early symptoms of congenital hemangioma—like a firm, purplish bump that’s present at birth—helps you seek the right care quickly. From there, the focus is on avoiding skin breakdown and bleeding, watching for rare strain on the heart, and following a plan with your child’s care team.
Ask for evaluation by a pediatric dermatologist or a vascular anomalies team soon after birth. Early confirmation of the diagnosis helps tailor follow-up and imaging if needed.
Sudden growth, darkening, or skin breakdown can raise the risk of bleeding or infection. Seek prompt medical advice if you notice these changes or if the area becomes very painful.
Keep the skin moisturized and avoid rubbing from seams, straps, or diapers. Soft clothing and careful diaper changes can lower the chance of irritation and ulcers on a congenital hemangioma.
Do not pick at scabs or crusts, and keep nails trimmed to avoid scratching. If bleeding occurs, apply steady pressure with clean gauze and seek medical care if it does not slow.
Transmission
Congenital hemangioma develops before birth and is present at delivery; it is not infectious and does not spread between people. In most families, there is no inherited pattern—these growths usually happen as a one-time, chance change in the developing blood vessels of the fetus. Because of that, genetic transmission of congenital hemangioma is considered rare, and the chance of it happening again in a future pregnancy is generally low. If you’re concerned about how congenital hemangioma is inherited in your family, a genetics or dermatology specialist can review your history and discuss recurrence risk.
When to test your genes
Consider genetic testing if multiple family members have unusual vascular birthmarks, if a newborn’s hemangioma is large, ulcerated, or in a high‑risk location, or if there are additional features like limb asymmetry or overgrowth. Testing helps confirm the subtype, guide imaging, and tailor care. Ask your clinician or a genetic counselor about timing and options.
Diagnosis
Congenital hemangioma is often recognized at birth by its distinct look and feel on the skin. The diagnosis of congenital hemangioma is usually made on exam and confirmed with imaging if needed to understand depth and blood flow. Doctors usually begin with a close skin exam and a review of pregnancy and birth details. Tests help tell it apart from other vascular birthmarks and check for rare high-flow effects on the heart.
The lesion’s color, borders, and firmness are assessed right away after birth. Features such as being fully formed at birth and a central pale area can suggest congenital hemangioma. Noting whether it shrinks, stays the same, or partly shrinks over time also helps.
Your provider asks about pregnancy ultrasounds, timing at birth, and any changes seen in the first weeks. Photos from home can show whether the spot is getting smaller or staying stable. Family history is reviewed, although most cases are not inherited.
Sound waves map the size and depth of the lesion and measure how fast blood is moving inside it. This helps confirm a high-flow pattern and spot feeding and draining vessels. Results guide whether more imaging or treatment planning is needed.
Detailed scans show how deep the hemangioma goes and its relationship to muscles, nerves, and nearby structures. They also outline blood vessel pathways and flow. This is especially useful for large or tricky locations, like the face or near joints.
Stages of Congenital hemangioma
Congenital hemangioma does not have defined progression stages. This is because it’s already fully formed at birth and then may shrink quickly, stay about the same size, or shrink only partway—so its course varies by type rather than moving through set steps. Diagnosis is usually based on appearance and location at birth, plus how it changes over the first weeks to months; early symptoms of congenital hemangioma are often a firm, raised skin area or patch noticed right away. Different tests may be suggested to help confirm the diagnosis, such as an ultrasound (sometimes MRI) to look at blood flow, and follow-up checks with photos are used to monitor any changes over time.
Outlook and prognosis
Many people ask, “What does this mean for my future?”, especially right after a diagnosis of congenital hemangioma. Most congenital hemangiomas are present at birth, then either shrink on their own over months (the rapidly involuting type) or stay about the same size (the non‑involuting type). Early symptoms of congenital hemangioma can include a firm, bluish‑purple bump and visible surface veins; for most babies, these change slowly and cause little trouble beyond appearance. The outlook is not the same for everyone, but most children do well with watchful care and occasional treatments to manage bulk, skin breakdown, or discomfort.
Looking at the long-term picture can be helpful. Rapidly involuting lesions often shrink a lot in the first year or two, sometimes leaving loose skin, pale patches, or small veins that can be improved later with laser or surgery. Non‑involuting lesions tend to persist, and families may weigh treatment for cosmetic reasons or if the mass interferes with movement or feeding, depending on where it sits. Serious complications like bleeding that won’t stop, heart strain from very high blood flow, or ulceration are uncommon and usually show up early; when they do, teams step in with wound care, medicines to ease blood flow, or timely surgery.
Prognosis refers to how a condition tends to change or stabilize over time. For congenital hemangioma, life expectancy is normal, and mortality is rare in modern care settings. Most kids grow and develop like their peers, and long-term health depends more on location and blood‑flow features than on size alone. Talk with your doctor about what your personal outlook might look like, including which type of congenital hemangioma is present, what to watch for at home, and when to consider treatment versus continued observation.
Long-term effects
Many living with congenital hemangioma want to know what the long run looks like day to day. While early symptoms of congenital hemangioma are present at birth, the long-term picture depends mostly on whether the growth shrinks on its own or stays about the same size. Long-term effects vary widely, from barely noticeable skin changes to a persistent, firm lump. Location matters too—spots near the eye, nose, or mouth can affect function more than those on the trunk or limb.
Some lesions shrink quickly in the first months of life and keep fading over the first year. As they recede, the area may leave behind thinner skin, small veins, or a soft dip.
Other lesions stay about the same size over time, remaining firm and raised. These often keep a purplish color and visible surface veins.
A portion may fade while a core lump remains. The leftover area can feel rubbery and look bluish or gray.
After shrinking, the skin can look stretched, thin, or slightly wrinkled. Small, red surface veins may remain visible.
How is it to live with Congenital hemangioma?
Living with a congenital hemangioma often means navigating something very visible from day one, then watching it change over time—some shrink quickly in infancy, others stay about the same size, and a few can cause issues like pain, skin breakdown, or bleeding that need medical care. Day to day, families manage gentle skin care, protect the area from bumps or sun, and keep follow-up visits to track growth, blood flow, and any effects on movement or nearby structures. For many, the emotional load is as real as the physical one: parents field questions in public, children may face curiosity or teasing, and loved ones learn to balance vigilance with normal play and routines. With clear guidance from clinicians and support at school and home, most families find a steady rhythm, building confidence in what to watch for and how to advocate when needed.
Treatment and drugs
Treatment for congenital hemangioma depends on size, location, blood flow, and whether it causes problems like pain, bleeding, ulceration, or pressure on nearby structures. Many congenital hemangiomas shrink on their own in the first months to years of life, so careful monitoring with scheduled check-ins is often the first step, and supportive care can make a real difference in how you feel day to day. When treatment is needed, options can include wound care for skin breakdown, pain control, compression, and targeted procedures such as sclerotherapy (injecting medicine to shrink vessels) or surgery to remove the lesion, especially if it interferes with vision, breathing, feeding, or movement. Medicines that ease symptoms are called symptomatic treatments, and while common infantile-hemangioma drugs like propranolol usually don’t work for congenital hemangioma, specialists may consider other medicines in select cases based on the lesion’s features. Your doctor can help weigh the pros and cons of each option, and may involve a team—often dermatology, interventional radiology, and surgery—to choose the safest plan for your child.
Non-drug treatment
For many families, the first step is careful observation to see how the birthmark changes over time and whether it affects comfort or function. Non-drug treatments often lay the foundation for managing congenital hemangioma, especially when medicines are unlikely to help. When early symptoms of congenital hemangioma, like a firm, purplish patch present at birth, are stable, doctors may recommend watchful waiting. If the lesion bleeds, ulcerates, or limits movement, targeted procedures and supportive care can reduce risks and improve appearance.
Regular check-ins track size, color, and any bleeding or pain. Many congenital hemangiomas shrink or stay stable, so avoiding procedures can be safest. Your team will tailor the timing of visits and photos to your child’s needs.
Gentle cleansing, fragrance-free moisturizers, and soft dressings protect fragile skin. This can lower the chance of cracking or ulcers and reduce pain from rubbing. Your clinician may show you how to pad clothing or diapers to prevent friction.
Soft, well-fitted sleeves or wraps can limit swelling and protect the surface. Compression may also help with discomfort from veins feeding the lesion. Fit should be checked regularly as children grow.
Pulsed-dye or similar lasers target surface blood vessels to lighten color and curb bleeding. This is often used for thin, superficial areas of a congenital hemangioma. Several sessions may be needed for the best result.
Your genes may have an impact on how drugs work for you
Some treatments for congenital hemangioma interact with your genes, which can change how well a drug works or how your body handles it. Genetic differences may influence response to beta-blockers, risk of side effects, and dosing needs, guiding personalized care.
Pharmacological treatments
Medicines play a limited role in congenital hemangioma because these birthmarks are fully formed at birth; drugs are mainly used for pain, skin breakdown, or infection rather than shrinking the lesion. Not everyone responds to the same medication in the same way. Early symptoms of congenital hemangioma—such as a firm bluish lump noted right after delivery—usually do not call for medicine unless there’s pain or skin problems.
Sometimes tried because it helps infantile hemangiomas, but congenital hemangioma often responds poorly. It may be considered case-by-case by a vascular anomalies specialist. If one option isn’t effective, second-line or alternative drugs may be offered.
For small, superficial areas, it may slightly lighten color or reduce surface prominence in some people with congenital hemangioma. Evidence is limited, so doctors use it selectively.
Used off-label for complex vascular anomalies, it may be considered in severe congenital hemangioma with pain, ulceration, or function-limiting features. It requires close monitoring, blood tests, and infection precautions.
These typically do not shrink congenital hemangioma, but a short course may be used for significant inflammation or swelling. Side effects limit use and dosing is carefully tapered.
Genetic influences
People often ask whether congenital hemangioma is inherited. It’s natural to ask whether family history plays a role. Most congenital hemangiomas happen sporadically, from gene changes that arise in the blood vessel cells of the developing skin before birth, rather than being passed down from a parent. These changes are usually limited to the hemangioma itself, so relatives and future pregnancies typically aren’t at higher risk. Research shows these changes affect the growth signals that tell blood vessels when to form and when to stop, but they’re found only in the hemangioma, not throughout the body. For these reasons, genetic testing for congenital hemangioma is not routinely done, though a clinician may suggest it in rare, atypical cases.
Is Congenital hemangioma genetic?
Genetics play a limited role in congenital hemangioma. Most cases are sporadic, linked to changes in growth signals in the affected area before birth, not inherited. Rarely, somatic gene variants in blood-vessel pathways are found, without clear family patterns.
Pharmacogenetics—how genetics influence drug effects
For most families, treatment choices focus on how the lesion behaves—whether a congenital hemangioma shrinks on its own, stays stable, or causes symptoms that need care. Unlike infantile hemangioma, congenital hemangioma generally does not respond to the beta-blocker propranolol, which is why the drugs used to treat congenital hemangioma are different. The genetic changes that drive a congenital hemangioma are usually confined to the birthmark itself and not inherited, and while they help doctors classify the type, they currently don’t point to a standard gene‑targeted treatment. Genetics is only one factor in how medicines work, and most decisions for the treatment of congenital hemangioma still rely on the lesion’s size, location, and complications. Pharmacogenetics becomes more relevant for supportive medicines—like pain relievers after a procedure—because codeine and tramadol can be unsafe or ineffective in people who process these drugs unusually fast or slow, and testing can guide safer choices. Targeted drugs such as sirolimus are rarely used for congenital hemangioma; when they are considered for complex cases, dosing is guided by careful monitoring rather than routine genetic testing. At this time, there isn’t a genetic test that predicts whether a congenital hemangioma will shrink or respond to a specific medicine.
Interactions with other conditions
Living with a congenital hemangioma can intersect with other health issues, especially when the lesion is large or has fast blood flow. In newborns, that extra circulation can strain the heart and, in some cases, contribute to high-output heart failure, particularly when the hemangioma is in the liver. Doctors call it a “comorbidity” when two conditions occur together. Bleeding or bruising disorders can complicate care, since early symptoms of congenital hemangioma may resemble a bruise and any procedure around the area can carry a higher risk of bleeding. Skin breakdown can invite infection, and if someone also has eczema or reduced circulation, healing may be slower and pain can be worse. Unlike infantile hemangioma, congenital hemangioma isn’t usually linked with broader syndromes involving the brain, heart, or large arteries, and it rarely causes the severe platelet-trapping clotting problem seen in other vascular tumors. For many, routine illnesses don’t change the lesion much, but severe anemia, infection, or heart or liver disease can shift blood flow and make swelling, warmth, or pain from the congenital hemangioma more noticeable.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Families and communities once noticed patterns: some newborns arrived with a purplish, raised birthmark that seemed fully formed at birth, sometimes with a pale rim or visible tiny blood vessels. Grandparents might recall a baby photo where a round mark sat on the scalp or over an arm, and how it changed—or didn’t—over the first year. These everyday observations shaped early ideas long before doctors sorted out what made these marks different from other vascular birthmarks.
First described in the medical literature as fully developed vascular tumors present at delivery, congenital hemangioma stood apart because it did not grow after birth the way infantile hemangioma typically does. Early reports focused on how some of these lesions shrank quickly in the first months (a pattern later called rapidly involuting) while others barely changed or only slowly softened over time. As careful case series accumulated, clinicians realized there were a few distinct patterns rather than one single type.
From early theories to modern research, the story of congenital hemangioma has been one of careful separation from look-alike conditions. For years, many lesions seen in the nursery were grouped together under one umbrella, which led to mixed advice about what to expect. Over time, descriptions became more precise: imaging features, the feel of the lesion on exam, and how the skin over it looked helped doctors tell congenital hemangioma apart from infantile hemangioma and other vascular malformations.
Advances in genetics added another layer, showing that congenital hemangioma is biologically different from the more common infantile hemangioma. Unlike infantile hemangioma, which often carries certain markers and follows a predictable growth-then-shrink pattern, congenital hemangioma lacks those markers and is already fully formed at birth. This biological distinction explained why early symptoms of congenital hemangioma—such as a firm, warm, bluish-purple nodule present on day one—did not match the course families were told to expect based on infantile hemangioma.
In recent decades, awareness has grown as pediatric dermatology, radiology, and surgery teams compared outcomes and followed children over time. Care records and photo archives clarified which lesions tended to involute rapidly and which remained stable, leading to more tailored monitoring and, when needed, timely treatment for complications like ulceration or bleeding. Historical differences highlight why getting the name right matters: it sets expectations for how the lesion will behave and whether intervention is likely.
Looking back helps explain today’s approach. The modern view of congenital hemangioma builds on those early observations—what it looks like at birth, how it changes month by month, and what its internal blood flow shows on imaging. Each stage in history has added to the picture we have today, allowing families to receive clearer guidance from the first days of life.